We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 1-Euro zone economies' plucky Q4 belies troubled growth outlook

Fri, 29th Jan 2021 11:37

* Germany and Spain eke out narrow Q4 growth

* France contracts by less than expected

* But vaccine roll-out issues, restrictions blight outlook

* IMF sees euro zone recovery lagging U.S., Japan

By Paul Carrel and Leigh Thomas

BERLIN/PARIS, Jan 29 (Reuters) - Growth in Germany and Spain
and a smaller-than-expected contraction in France pointed to
resilience in the euro zone economy in the final three months of
last year, but the bright spot belies a more troubled outlook
for the bloc.

In Germany, robust exports helped Europe's largest economy
eke out 0.1% growth in the fourth quarter, staving off
contraction despite a second wave of the new coronavirus
slamming the brakes on consumption, data showed on Friday.

France, the euro zone's second-largest economy, shrank 1.3%
in the final three months of 2020 after the country entered a
second coronavirus lockdown in October to contain a second wave
of infections.

Spain achieved timid quarterly growth of 0.4%. But that has
not stopped Spain from recording its worst-ever annual economic
contraction, with output falling 11% from 2019's level, official
data showed.

"Numbers for Germany, France and Spain showed that GDP was
relatively resilient in Q4," Nicola Nobile at Oxford Economics
wrote in a research note. But he added, "there are not many
indications that this dynamic could have continued in Q1."

"All in all, the disappointing vaccine roll-out so far, the
extension of restrictions in many European countries and the
latest data now point to continued weakness in the eurozone over
the coming months."

The French slump, which followed an 18.5% rebound in the
third quarter after a first lockdown, beat expectations for a 4%
contraction on average in a Reuters poll of 28 economists,
surpassing even the highest estimate of -1.4%.

But France is on tenterhooks to find out in the coming days
whether the government will put the country under a new lockdown
and in particular whether schools will be closed.

In Germany, Chancellor Angela Merkel and state leaders
agreed last week to extend a lockdown until mid-February as the
country, once a role model for fighting the pandemic, struggles
with a second wave and record daily numbers of COVID-19 deaths.

On Wednesday, German government slashed its growth forecast
to 3% this year, a sharp revision from last autumn's estimate of
4.4%, caused by a second coronavirus lockdown.

TRAILING U.S.

The economic outlook across the 19-country euro zone is
being muddied by a row between the European Union and
Anglo-Swedish firm AstraZeneca over its supply of
vaccines to the bloc, and by the return of inflation in Germany.

The International Monetary Fund said this week the euro area
is likely to slip behind the United States in its recovery.

"Recovery paths vary within the group, with the U.S. and
Japan projected to regain end-2019 activity levels in the second
half of 2021, while in the euro area and the United Kingdom
activity is expected to remain below end-2019 levels into 2022,"
the IMF said in its in its World Economic Outlook.

The AstraZeneca supply issue is a blow to Europe's COVID-19
vaccination drive, and the German inflation spike - consumer
prices turned positive and rose in January to 1.6% on the year -
adds to a complex mix of data for the European Central Bank to
assess.

ECB data released on Friday showed lending to euro zone
companies picked up last month though the bloc was probably back
in recession and banks said they were tightening access to
credit amid fear of defaults amid a fresh wave of lockdowns.

The ECB is unlikely to cut its already-record-low policy
because that would do little to revive the pandemic-hit euro
zone economy, five sources told Reuters, playing down concern
about a strong euro.

Traders were left scratching their head this week when Dutch
central bank governor Klaas Knot said the ECB "had room" to push
its Deposit Facility Rate, currently at minus 0.5%, further
below zero if needed to stem a rally in the euro EUR=.

The sources said Knot had raised the rate cut issue at the
ECB's policy meeting last week but the discussion was "marginal"
and not considered part of the ECB's policy strategy, which is
now focussed on bond purchases and cheap loans to banks.

"ECB communication could be such a powerful tool but is
really very confusing," BofA analysts said in a research note.

(Additional reporting by Belén Carreño and Joao Manuel Vicente
Mauricio in Madrid and by Francesco Canepa, Balazs Koranyi and
Frank Siebelt in Frankfurt; editing by Larry King)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.